Atractylenolide Ⅰ inhibit the proliferation of gastric cancer cells SGC-7901 by lowering Cyclin D1/CDK4 and its mechanism

Objective To investigate the inhibition of atractylenolide Ⅰ on the proliferation of gastric cancer cell line SGC-7901 and its possible mechanism.

Methods After the atractylenolide Ⅰ treatment, the inhibitory effects of atractylenolide Ⅰ on the proliferation of gastric cancer cells SGC-7901 were detected using MTT assay, the apoptosis rate and cell cycle of gastric cancer cells SGC-7901 were detected using flow cytometry, and the changes of Cyclin D1 and CDK4 proteins in gastric cancer cells SGC-7901 were detected using Western blotting.

Results The results of MTT assay showed that atractylenolide Ⅰ could inhibit the proliferation of gastric cancer cells SGC-7901 in a timeand dose-dependent manner compared with the control group(P < 0.05 to P < 0.01).The results of flow cytometry showed that the atractylenolide Ⅰ could significantly promote the apoptosis of gastric cancer cells SGC-7901(P < 0.01), increase the ratio of G₁ phase cells(P < 0.01), and decrease the ratio of G₂ phase cells in a dose-dependent manner compared with the control group(P < 0.01).The results of Western blotting showed that atractylenolide Ⅰ could reduce the expression levels of Cyclin D1 and CDK4 proteins in SGC-7901 cells in a dose-dependent manner compared with the control group(P < 0.01).

Conclusions Atractylenolide Ⅰ can inhibit the proliferation, and promote apoptosis of gastric cancer cells SGC-7901 by reducing the levels of Cyclin D1 and CDK4 protein to change cell cycle.